Dr Martin Landray
Martin Landray is a Reader in Epidemiology and Honorary Consultant Physician. His principal research interests are in the reliable evaluation of treatments, particularly in vascular and renal disease. He completed specialist training in General Internal Medicine and Clinical Pharmacology & Therapeutics in Birmingham, UK, and joined CTSU in November 2000.
He is co-principal investigator for a series of large-scale randomized trials, including:
SHARP: This international study demonstrated that lowering LDL-cholesterol reduces the risk of major atherosclerotic events among over 9000 patients with chronic kidney disease.
HPS2-THRIVE: This trial is investigating the effect of raising HDL-cholesterol using niacin/laropiprant on the risk of major vascular events among over 25,000 patients with vascular disease.
HPS3 / TIMI55 - REVEAL: This trial is investigating the effect of adding anacetrapib (a CETP-inhibitor) to effective LDL-lowering treatment with atorvastatin on the risk of major coronary events among 30,000 patients with vascular disease.
In addition he coordinated the development of bespoke IT systems to facilitate efficient recruitment and data capture for the UK Biobank observational cohort study, which successfully recruited 500,000 middle-aged individuals in less than 3.5 years.
Other work has focused on efforts to facilitate the conduct of large-scale clinical trials through improved regulations and promotion of efficient systems and procedures, including:
- FDA Clinical Trial Transformation Initiative: He has been a member of the Steering Committee since its initiation in 2008, co-leader of the Monitoring Project (2008-2011) and co-leader of the Quality by Design project (2012 - ).